Rheumatology News and Research

RSS

Rheumatology is a sub-specialty in internal medicine and pediatrics, devoted to the diagnosis and therapy of rheumatic diseases. Rheumatologists mainly deal with clinical problems involving joints, soft tissues and allied conditions of connective tissues.

Takeda, Affymax submit peginesatide NDA to FDA for treatment of anemia linked with chronic renal failure

Affymax, Inc. and Takeda Pharmaceutical Company Limited today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for the investigational agent peginesatide for the treatment of anemia associated with chronic renal failure in adult patients on dialysis.

31 May 2011

HHS uses new devices to meet growing need of joint replacements among baby boomers

"The number of patients in their 50s coming into my office asking for joint replacement is higher than ever," says Dr. Steven B. Haas, a knee surgeon at Hospital for Special Surgery in New York City.

30 May 2011

Positive data from Augurex's RA biomarker blood test, novel drug target presented at EULAR conference

Augurex Life Sciences Corp. today reported that in London at the European League Against Rheumatism Conference, leading arthritis researchers presented important data on Augurex's rheumatoid arthritis biomarker blood test and novel drug target.

30 May 2011

New positive Cimzia phase IIIb study data on rheumatoid arthritis presented at EULAR meeting

UCB today announced data which showed that the addition of Cimzia to current therapy was associated with a rapid and consistent clinical response in a diverse group of rheumatoid arthritis (RA) patients.

30 May 2011

AACE applauds legislation for preservation of access to osteoporosis testing for Medicare beneficiaries

The American Association of Clinical Endocrinologists (AACE) applauds the introduction of legislation in both the U.S. House of Representatives and the U.S. Senate that will preserve patient access to osteoporosis testing and treatment services under the Medicare program.

27 May 2011

Study: Cardiovascular disease may be under treated in rheumatoid arthritis patients

Results of a study, involving 98,454 patients demonstrated that at 30 days following their first heart attack, RA patients were approximately 20% less likely to be prescribed standard MI treatments, such as statins and betablockers, compared to healthy patients.

27 May 2011

Adalimumab plus methotrexate helps achieve higher levels of disease control in early RA

Data presented today at the EULAR 2011 Annual Congress demonstrated that initial treatment with adalimumab (Humira, ADA) plus methotrexate in early RA patients can provide high levels of disease control in many patients, and may also offer the opportunity to change future treatment options for some.

27 May 2011

Specific influenza immunization strategies for RA patients may be required for future flu pandemics

A Brazilian hospital-based study assessed responses to flu vaccines in 340 RA patients in regular follow-up compared to 234 healthy patients.

26 May 2011

HPV vaccination does not affect rate of disease flares in patients with SLE, study finds

Results of a Chinese study showed that the HPV vaccine did not have significant effects on the number of disease flares or antibody measures in patients with inactive SLE receiving stable doses of medications after administration, and therefore was determined safe to use to prevent HPV in this group of patients.

26 May 2011

BioCryst presents positive data from two BCX4208 Phase 2 studies in gout at EULAR 2011

BioCryst Pharmaceuticals, Inc. presented positive data from its two completed, randomized, double-blind, placebo-controlled Phase 2 studies of BCX4208 in patients with gout at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism in London, U.K.

26 May 2011

Patients with rheumatoid arthritis two times more likely to have concurrent COPD

Patients with rheumatoid arthritis are two times more likely to have concurrent chronic obstructive pulmonary disease than healthy controls -- an association which was sustained even when variables such as age, gender, smoking and obesity were controlled for, according to a study presented today at the EULAR 2011 Annual Congress.

26 May 2011

Tofacitinib safe and effective for patients with rheumatoid arthritis

Results of a Phase III study presented today at the EULAR 2011 Annual Congress show that at 6 months, 58.3 percent of patients who had previously not responded to treatment with DMARDs, achieved ACR20 response when treated with the novel oral Janus kinase inhibitor tofacitinib at 10mg BID compared to 31.2 percent in the placebo group. Significant improvements were also observed in the 5 mg BID dose.

26 May 2011

Impact of gaming devices on finger and wrist pain in children presented at EULAR 2011

For the first time, results on the impact of gaming devices on finger and wrist pain in children were presented today at the EULAR 2011 Annual Congress. Data comparing two schools in the USA demonstrate that young children experience high levels of pain following long term use of gaming devices and mobile phones indicating that excessive gaming may negatively impact on joint health.

26 May 2011

Ardea reports additional results from lesinurad-allopurinol Phase 2b study in hyperuricemia, gout

Ardea Biosciences, Inc. announced that additional positive clinical and preclinical results from its development program of lesinurad, the Company's lead product candidate for the treatment of hyperuricemia and gout, were presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism in London, UK.

26 May 2011

Two Novartis ACZ885 Phase III trial data in severe gouty arthritis to be presented at EULAR 2011

Novartis announced results of two pivotal Phase III trials in patients with severe gouty arthritis, showing that ACZ885 provided superior pain relief and reduced the risk of suffering new attacks by up to 68% compared to an injectable steroid used to treat gouty arthritis attacks.

25 May 2011

Vectra DA blood test may help predict patients' response to rheumatoid arthritis therapy

Crescendo Bioscience- today announced data indicating that Vectra- DA, a first-in-class multi-biomarker blood test used to assess rheumatoid arthritis disease activity, provides physicians with an objective measure which may help determine whether patients are responding to therapy.

25 May 2011

Azilsartan medoxomil-CLD phase 3 study results in systolic blood pressure presented at ASH 2011

Takeda Global Research & Development Center, Inc. U.S., today announced results from three phase 3 studies of the investigational fixed-dose combination of azilsartan medoxomil plus chlorthalidone.

24 May 2011

Tumor necrosis factor can suppress inflammation, treat rheumatoid arthritis

A new study by rheumatologists at Hospital for Special Surgery in New York has shown that a powerful pro-inflammatory protein, tumor necrosis factor, can also suppress aspects of inflammation.

23 May 2011

African Americans with SLE have higher antibody response to influenza vaccination: Study

New research shows that African Americans with systemic lupus erythematosus had a higher antibody response to influenza vaccination than European American patients.

21 May 2011

HSS researchers develop new tool to compare efficacy of different brachial plexus surgical treatments

The way that clinicians report outcomes of surgery for a traumatic nerve injury involving the arm is not standardized, and it is thus difficult to compare the efficacy of different surgical treatments, according to a study by researchers at Hospital for Special Surgery (HSS) in New York.

20 May 2011

Rheumatology News and Research

Further Reading

Takeda, Affymax submit peginesatide NDA to FDA for treatment of anemia linked with chronic renal failure

HHS uses new devices to meet growing need of joint replacements among baby boomers

Positive data from Augurex's RA biomarker blood test, novel drug target presented at EULAR conference

New positive Cimzia phase IIIb study data on rheumatoid arthritis presented at EULAR meeting

AACE applauds legislation for preservation of access to osteoporosis testing for Medicare beneficiaries

Study: Cardiovascular disease may be under treated in rheumatoid arthritis patients

Adalimumab plus methotrexate helps achieve higher levels of disease control in early RA

Specific influenza immunization strategies for RA patients may be required for future flu pandemics

HPV vaccination does not affect rate of disease flares in patients with SLE, study finds

BioCryst presents positive data from two BCX4208 Phase 2 studies in gout at EULAR 2011

Patients with rheumatoid arthritis two times more likely to have concurrent COPD

Tofacitinib safe and effective for patients with rheumatoid arthritis

Impact of gaming devices on finger and wrist pain in children presented at EULAR 2011

Ardea reports additional results from lesinurad-allopurinol Phase 2b study in hyperuricemia, gout

Two Novartis ACZ885 Phase III trial data in severe gouty arthritis to be presented at EULAR 2011

Vectra DA blood test may help predict patients' response to rheumatoid arthritis therapy

Azilsartan medoxomil-CLD phase 3 study results in systolic blood pressure presented at ASH 2011

Tumor necrosis factor can suppress inflammation, treat rheumatoid arthritis

African Americans with SLE have higher antibody response to influenza vaccination: Study

HSS researchers develop new tool to compare efficacy of different brachial plexus surgical treatments

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News